Portal Vein Thrombosis Clinical Trial
After successful screening the cases of cirrhosis of liver irrespective of the etiology who have non tumor portal vein thrombosis will be enrolled. The baseline Doppler parameter will be recorded and the patient will be randomized into either interventional (acenocoumarol) or placebo group along with first five days of subcutaneous Low Molecular Weight Heparin inj. Enoxaparin in the interventional arm and placebo injection in the control arm. Every 3 monthly the Doppler screening for recanalization of portal vein thrombus will be done with monitoring of International Normalized Ratio (INR)with target INR 2-3. Both the groups will receive the therapy for one year irrespective of the Doppler findings in relation to portal vein thrombus re-canalization.Then one year drug free monitoring will be done in both the groups as per the primary or secondary outcome. .
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03631147 -
The Effect of Rifaximin on Portal Vein Thrombosis
|
N/A | |
Completed |
NCT02250391 -
Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis
|
Phase 3 | |
Recruiting |
NCT05625893 -
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion
|
Phase 2 | |
Completed |
NCT05012501 -
Analysis of Neutrophil Extracellular Traps in Hypercoagulability and Portal Vein Thrombosis in Liver Cirrhosis Patients
|
||
Terminated |
NCT00769873 -
Anticoagulation Post Laparoscopic Splenectomy
|
Phase 2 | |
Recruiting |
NCT05123326 -
Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome
|
||
Completed |
NCT01095185 -
Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding
|
Phase 3 | |
Completed |
NCT02585713 -
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
|
Phase 3 | |
Not yet recruiting |
NCT06117488 -
Risk Factors and Management Outcome of Chronic Portal Vein Thrombosis in Children
|
||
Completed |
NCT01326949 -
Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis
|
N/A | |
Not yet recruiting |
NCT05339581 -
IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation
|
N/A | |
Recruiting |
NCT03902678 -
Role of EUS Guided FNA of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma
|
N/A | |
Not yet recruiting |
NCT06319131 -
Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT
|
N/A | |
Recruiting |
NCT03193502 -
Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis
|
Phase 3 | |
Completed |
NCT03201367 -
Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV
|
N/A | |
Completed |
NCT03477149 -
EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications
|
N/A | |
Recruiting |
NCT02398357 -
The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis
|
Phase 4 | |
Completed |
NCT01556282 -
TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis
|
N/A | |
Recruiting |
NCT04433481 -
Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis
|
N/A | |
Not yet recruiting |
NCT05872841 -
H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis
|
Phase 2 |